If You Invested in Merus (MRUS)

Merus N.V. (Nasdaq: MRUS) is an oncology-focused biotechnology company that develops full-length human bispecific and trispecific antibody therapeutics, which it refers to as Multiclonics®. According to the company’s disclosures, these Multiclonics® antibodies are manufactured using industry-standard processes and have been observed in preclinical and clinical studies to share several features with conventional human monoclonal antibodies, such as long half-life and low immunogenicity. Merus operates in the pharmaceutical preparation manufacturing industry within the broader manufacturing sector.

Merus has created multiple proprietary antibody formats, including Biclonics®, Triclonics® and ADClonics®. These formats support the development of multispecific antibody therapeutics and antibody drug conjugates that are being evaluated across a range of solid tumors. The company describes itself as an oncology company focused on advancing these multispecific antibodies and antibody drug conjugates through clinical development.

Core Programs and Therapeutic Focus

A key program in the Merus pipeline is petosemtamab (also known as MCLA-158), which the company describes as a Biclonics® antibody targeting epidermal growth factor receptor (EGFR) and leucine-rich repeat containing G-protein-coupled receptor 5 (LGR5). Merus reports that petosemtamab is being evaluated in solid tumors, including recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) and metastatic colorectal cancer (mCRC). The company has disclosed phase 2 and phase 3 clinical trials of petosemtamab in these indications, including combinations with standard chemotherapies such as FOLFOX and FOLFIRI, and with pembrolizumab in PD-L1 positive recurrent or metastatic HNSCC.

Merus has also disclosed that petosemtamab has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) in two settings related to recurrent or metastatic HNSCC: in combination with pembrolizumab for first-line PD-L1 positive disease with a combined positive score ≥ 1, and as monotherapy for patients whose disease has progressed following platinum-based chemotherapy and prior PD-1 or PD-L1 therapy.

Beyond petosemtamab, Merus reports additional clinical and preclinical programs based on its multispecific platforms. These include MCLA-129, described as an EGFR x c-MET Biclonics® antibody being investigated in non-small cell lung cancer (NSCLC), and collaborations that apply its Triclonics® platform to trispecific T-cell engagers. The company also notes that its Multiclonics® platform underpins multiple discovery and development-stage programs pursued both internally and with partners.

Approved Product and Commercial Partnerships

Merus has disclosed an FDA-approved product, BIZENGRI® (zenocutuzumab-zbco), described as a HER2 x HER3 Biclonics® antibody. According to the company, BIZENGRI® is approved in the United States for adults with pancreatic adenocarcinoma or non–small cell lung cancer that are advanced unresectable or metastatic and harbor a neuregulin 1 (NRG1) gene fusion after disease progression on or after prior systemic therapy. Merus states that it has exclusively licensed to Partner Therapeutics, Inc. the right to commercialize BIZENGRI® for the treatment of NRG1+ cancer in the U.S., while Merus continues to be involved in supplying commercial material and receiving related revenue.

In addition to this U.S. commercialization arrangement, Merus reports several research and development collaborations with larger biopharmaceutical companies. These include a global collaboration and license agreement with Incyte Corporation focused on bispecific antibodies using the Biclonics® platform, a research collaboration and exclusive license agreement with Eli Lilly and Company to develop CD3-engaging T-cell redirecting bispecific antibodies, a collaboration with Gilead Sciences to discover trispecific T-cell engagers using the Triclonics® platform, a license agreement with Ono Pharmaceutical Co., Ltd. for certain Biclonics® candidates, and a research collaboration and license agreement with Biohaven to co-develop bispecific antibody drug conjugates.

Corporate Structure and Acquisition by Genmab

Merus is organized as a Dutch public limited liability company (naamloze vennootschap) under the laws of The Netherlands. Its common shares, with a nominal value of €0.09 per share, have been listed on The Nasdaq Global Market under the symbol MRUS. In a transaction agreement disclosed in an 8-K filing dated September 29, 2025, Merus agreed to be acquired by Genmab A/S, a Danish biotechnology company, through a tender offer for all issued and outstanding Merus common shares at a cash price of $97.00 per share, followed by back-end transactions intended to result in Merus becoming an indirect wholly owned subsidiary of Genmab.

An 8-K filed on December 12, 2025 reports that the tender offer expired on December 11, 2025, and that Genmab’s wholly owned subsidiary accepted for payment all Merus common shares validly tendered and not properly withdrawn, representing approximately 94.2% of the issued and outstanding share capital of Merus. The filing states that this resulted in a change of control and describes the commencement of a subsequent offering period and the intention to complete back-end transactions to acquire 100% of the common shares. The September 29, 2025 8-K further indicates that, following completion of these steps, Merus will, at Genmab’s request, cause the delisting of its common shares from the Nasdaq Stock Market and subsequently deregister the shares under the Securities Exchange Act of 1934, ending its reporting obligations.

These filings indicate that MRUS represents a company transitioning from an independent Nasdaq-listed issuer to a subsidiary within Genmab’s corporate group. Investors researching the MRUS symbol should be aware that the acquisition process and planned delisting and deregistration affect the trading status and public reporting profile of the company.

Research, Development and Collaborations

Merus’ public updates emphasize extensive research and development activity centered on its multispecific antibody platforms. The company reports multiple ongoing clinical trials for petosemtamab in head and neck squamous cell carcinoma and metastatic colorectal cancer, including phase 3 registration trials in first-line and later-line recurrent or metastatic HNSCC and a phase 2 trial in various lines of therapy for mCRC. Interim data releases describe antitumor activity, safety observations, and response rates in these studies, as well as presentations at major oncology conferences.

Merus also discloses collaborations that extend the reach of its technology platforms. The Incyte collaboration involves multiple discovery and development programs using Biclonics® technology, with Merus eligible for reimbursement of research activities, potential milestones and sales royalties. The Lilly collaboration focuses on CD3-engaging T-cell redirecting bispecific antibodies, with Merus contributing its Biclonics® platform and CD3 panel. The Gilead collaboration is aimed at discovering trispecific T-cell engagers using Triclonics®, with Merus leading early-stage research for specified programs. The Biohaven collaboration combines Merus’ Biclonics® technology with Biohaven’s antibody drug conjugate technologies to generate bispecific ADCs under shared development and commercialization arrangements, subject to mutual advancement decisions.

Capital Markets and Corporate Activity

Merus’ filings and news releases describe various corporate and capital markets activities typical for a clinical-stage biotechnology company. These include public offerings of common shares, inducement grants of stock options to new employees under Nasdaq Listing Rule 5635(c)(4), and conference presentations at healthcare and growth-focused investor events. The company’s financial disclosures outline revenue contributions from collaboration agreements and product-related activities, as well as research and development expenses associated largely with clinical trial support and manufacturing for programs such as petosemtamab.

Through these activities, Merus positions its Multiclonics® platform and oncology pipeline as central to its business, while the acquisition by Genmab, as documented in its SEC filings and joint company announcements, marks a significant change in its corporate trajectory and future reporting status.